SonALAsense
Signal active
Organization
Contact Information
Overview
SonALAsense develops SDT (Sonodynamic Therapy) intended to turn glioblastoma multiforme (GBM) patients into cancer survivors. It utilizes MRI-guided focused ultrasound (the device) in combination with aminolevulinic acid (a drug) to selectively target and kill tumor cells. Their use of an MRI-guided focused ultrasound device with ALA is a true drug-device combination, where both the drug and the device are required for a therapeutic effect. SDT has a well-elucidated mechanism of action (creation of reactive oxygen species).
The company was founded in 2019 and is based in Berkeley, California.
About
Industries
Biotechnology, Health Care, Medical, Health Diagnostics
Founded
2019
Employees
1-10
Headquarters locations
United States, North America
Social
N/A
Profile Resume
SonALAsense headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Health Diagnostics sector. The company focuses on Biotechnology and has secured $675.0M in funding across 32 round(s). With a team of 1-10 employees, SonALAsense is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - SonALAsense, raised $20.1M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
0
Lead Investors
0
Total Funding Amount
$21.1M
Details
1
SonALAsense has raised a total of $21.1M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2022 | Early Stage Venture | 20.1M |
Investors
There is no investor info for this profile.
Recent Activity
There is no recent news or activity for this profile.